Sanofi (SNYNF) Change in Working Capital (2009 - 2026)
Sanofi (SNYNF) posted Change in Working Capital of -$406.2 million for Q1 2026, down 116.66% sequentially from $2.4 billion in Q4 2025, and down 302.3% YoY from $200.8 million in Q1 2025.
Sanofi (SNYNF) Change in Working Capital (2009 - 2026) Analysis & Trends
Sanofi (SNYNF) has 18 years of Change in Working Capital data on file, last reported at -$406.2 million in Q1 2026.
- Quarterly Change in Working Capital fell 302.3% year-over-year to -$406.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 272.09% YoY) and the FY2025 annual result came in at $317.8 million, up 337.33% from the prior year.
- Change in Working Capital declined to -$406.2 million in Q1 2026 per SNYNF's latest filing, from $2.4 billion in the prior quarter.
- The five-year high for Change in Working Capital was $2.4 billion in Q4 2025, with the low at -$2.6 billion in Q3 2024.
- Average Change in Working Capital over 5 years is -$184.1 million, with a median of -$253.6 million recorded in 2026.
- Year-over-year, Change in Working Capital slumped 343.26% in 2024 and jumped 550.12% in 2025.
- Sanofi's Change in Working Capital stood at -$486.7 million in 2022, then surged by 145.77% to $222.7 million in 2023, then tumbled by 343.26% to -$541.8 million in 2024, then jumped by 550.12% to $2.4 billion in 2025, then plunged by 116.66% to -$406.2 million in 2026.
- Business Quant data shows SNYNF's Change in Working Capital at -$406.2 million in Q1 2026, $2.4 billion in Q4 2025, and $35.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Working Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.51 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -787.00 Mn |
| 10 | Sanofi | - | - | 9.49 Bn | -406.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -406.25 Mn |
| Mar 31, 2026 | -406.25 Mn |
| Dec 31, 2025 | 2.44 Bn |
| Dec 31, 2025 | 2.44 Bn |
| Sep 30, 2025 | 35.07 Mn |
| Sep 30, 2025 | 35.07 Mn |
| Jun 30, 2025 | 228.66 Mn |
| Jun 30, 2025 | 228.66 Mn |
| Mar 31, 2025 | -100.98 Mn |
| Mar 31, 2025 | -100.98 Mn |
| Dec 31, 2024 | -541.78 Mn |
| Dec 31, 2024 | -541.78 Mn |
| Sep 30, 2024 | -2.56 Bn |
| Sep 30, 2024 | -2.56 Bn |
| Jun 30, 2024 | 1.87 Bn |
| Jun 30, 2024 | 1.87 Bn |
| Mar 31, 2024 | -1.86 Bn |
| Mar 31, 2024 | -1.86 Bn |
| Dec 31, 2023 | 222.72 Mn |
| Dec 31, 2023 | 222.72 Mn |